Patents by Inventor Alistair James Henry
Alistair James Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220332709Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.Type: ApplicationFiled: June 20, 2019Publication date: October 20, 2022Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Suganthan Selvaratnam, Giancarlo Trani, Zhaoning Zhu
-
Publication number: 20220235146Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: ApplicationFiled: December 3, 2021Publication date: July 28, 2022Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
-
Patent number: 11214627Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: GrantFiled: June 8, 2017Date of Patent: January 4, 2022Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
-
Publication number: 20190144565Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: ApplicationFiled: June 8, 2017Publication date: May 16, 2019Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
-
Patent number: 10048253Abstract: The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) Binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) Providing a test compound which has a low molecular weight, (c) Evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) Select a compound from step c) based on the ability to bind to the protein or fragment thereof.Type: GrantFiled: June 28, 2013Date of Patent: August 14, 2018Assignee: UCB BIOPHARMA SPRLInventors: Alastair David Griffiths Lawson, Alistair James Henry
-
Publication number: 20180037646Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: September 7, 2017Publication date: February 8, 2018Applicant: UCB BIOPHARMA SPRLInventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi
-
Publication number: 20150219635Abstract: The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) Binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) Providing a test compound which has a low molecular weight, (c) Evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) Select a compound from step c) based on the ability to bind to the protein or fragment thereof.Type: ApplicationFiled: June 28, 2013Publication date: August 6, 2015Inventors: Alastair David Griffiths Lawson, Alistair James Henry
-
Patent number: 8679494Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: April 22, 2009Date of Patent: March 25, 2014Assignee: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistair James Henry
-
Publication number: 20110262443Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: April 22, 2009Publication date: October 27, 2011Applicant: UCB PHARMA S.A.Inventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi
-
Patent number: 8003108Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 25, 2006Date of Patent: August 23, 2011Assignees: Amgen Inc., UCB SAInventors: Hsieng Sen Lu, Christpher Paszty, Martyn Kim Robinson, Alistair James Henry, Kelly Sue Warmington, John Latham, Alastair Lawson, David Winkler, Aaron George Winters
-
Publication number: 20090304713Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: ApplicationFiled: November 24, 2008Publication date: December 10, 2009Applicants: AMGEN INC., UCB PHARMA S.A.Inventors: Christoper Paszty, Martin Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron George Winters
-
Patent number: 7592429Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 25, 2006Date of Patent: September 22, 2009Assignees: UCB SA, Amgen Inc.Inventors: Christopher Paszty, Martyn Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David Winkler, Aaron George Winters